Articles Tagged With: tetracycline
-
Omadacycline (Nuzyra)
Omadacycline was approved in 2018 by the U.S. Food and Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
-
Eravacycline (Xerava)
-
Tetracycline for Multiple Sclerosis?
One hundred forty-two patients within 180 days of their first demyelinating event were randomized to minocycline 100 mg BID vs. placebo. The unadjusted risk of conversion to multiple sclerosis within six months after randomization was 61.0% in the placebo group and 33.4% in the minocycline group. At 24 months, the effect of minocycline was not statistically significant.
-
Infectious Disease Alert Updates
Travel Recommendations for Hajj; Dung and Tetracycline